<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03112993</url>
  </required_header>
  <id_info>
    <org_study_id>IRB # 2008066</org_study_id>
    <secondary_id>MISP # 56051.</secondary_id>
    <nct_id>NCT03112993</nct_id>
  </id_info>
  <brief_title>Speed of Recovery of Reversal of Neuromuscular Blockade in Geriatric Patients Undergoing Spine Surgery</brief_title>
  <official_title>A Prospective, Randomized, Double-Blind Clinical Trial Evaluating the Speed of Recovery and Safety of Reversal of Neuromuscular Blockade With Sugammadex (Bridion™) Versus Neostigmine in Geriatric Patients Undergoing Spine Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Missouri-Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Missouri-Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Spine surgery is one of the most common operative procedures in the United States. It is
      performed in the prone position (a patient laying on belly). Muscle relaxants are given for
      neuromuscular blockade often referred as paralysis for surgical exposure which is maintained
      until the patient is returned to the supine position (a patient laying on back) at the end of
      surgery. At the end of the surgery the paralysis is reversed with a drug (neostigmine). A new
      drug (sugammadex) has the ability to rapidly reverse the paralysis but it is not well
      investigated in elderly. This study will investigate speed of recovery and complications of
      the two reversal drugs in elderly patients (age ≥ 65 years) undergoing posterior spine
      surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The elderly (age ≥ 65 years) population is the fastest growing segment of the American
      population. Spine surgery is one of the most common operative procedures in the United States
      and, as the population ages, a larger percentage of geriatric patients will require this
      procedure. In addition, spinal surgery is often more complex in the elderly population,
      resulting in longer surgical times. A previous study reported that the rate of complex
      procedures increased 15-fold in Medicare recipients. Spine surgery is performed in the prone
      position and neuromuscular blockade (NMB) is maintained until the patient is returned to the
      supine position at the end of surgery to avoid the risk of patient movement, injury, and
      inadvertent tracheal extubation while prone. Currently, NMB is reversed with neostigmine
      immediately after turning the patients back to the supine position at the end of the
      procedure.

      Rocuronium bromide, an intermediate-acting neuromuscular blocking agent (NMBA), is used in
      approximately 60% of surgical cases in the United States and is commonly used for muscle
      relaxation during spinal surgery. With aging, the clearance and half-life of rocuronium is
      prolonged resulting in a wide variability in the duration of action and time to reversal.
      Until recently, the only medication available for the reversal of neuromuscular blockade was
      neostigmine and postoperative residual neuromuscular block (PRNB) was common, especially in
      elderly patients. A recent study reported that PRNB occurred in 58% of elderly patients who
      were maintained at a moderate level (2 twitches in the TOF) of muscle relaxation with
      rocuronium during elective surgery. As a result, these older adults experienced an increased
      incidence of airway obstruction, hypoxemic events, muscle weakness, postoperative pulmonary
      complications, and increased PACU and hospital lengths of stay.

      A new neuromuscular reversal agent sugammadex (Bridion®) has the ability to rapidly reverse
      both moderate and deep rocuronium-induced NMB. Another study reported that the mean time to
      complete reversal (TOF ratio ≥ 0.9) of a moderate block (2 twitches in the TOF) with
      sugammadex in geriatric patients was 2.9 minutes, which was only 1 minute longer than in
      younger patients. Reversal of NMB with neostigmine is much slower and it is reported to take
      approximately 19 minutes to achieve complete reversal in middle-aged patients. There is
      little available data on the NMB reversal time in older adults, but it will likely be even
      longer because the age-related physiologic changes prolong neuromuscular recovery. Thus,
      sugammadex has the potential to more rapidly reverse NMB in geriatric patients at the end of
      surgery. As a result, the use of sugammadex should decrease time in the OR and possibly PACU
      time and result in cost savings.

      Neostigmine has cardiac muscarinic effects and, therefore, has to be administered with an
      anticholinergic agent such as glycopyrrolate to counteract these effects. A previous study
      found a 16% incidence of cardiac dysrhythmias in elderly patients who received
      neostigmine/glycopyrrolate NMB reversal. The ability of sugammadex to completely reverse NMB
      without the addition of an anticholinesterase agent should result in an improved safety
      profile in elderly patients.

      The goal of this prospective, randomized, double-blinded controlled trial is to test the
      hypothesis that the reversal of neuromuscular blockage with sugammadex as compared to
      neostigmine in geriatric patients will provide a shorter time to complete recovery of
      neuromuscular function, improve the workflow in the operating room and decrease operative
      costs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 30, 2017</start_date>
  <completion_date type="Actual">August 14, 2018</completion_date>
  <primary_completion_date type="Actual">August 13, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will receive (per a randomization schedule) either sugammadex, or neostigmine/glycopyrrolate to reverse neuromuscular blockade at the end of the surgery. The reversal agent will be prepared in a blinded fashion.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The surgeon, anesthesiologist, operating room staff, patients, personnel in the postanesthesia care unit (PACU) as well as the investigators collecting the postoperative data will be blinded to the group allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in Time of Neuromuscular Recovery From a Neuromuscular Moderate Blockade</measure>
    <time_frame>Day 1</time_frame>
    <description>Speed of neuromuscular recovery in minutes measured by recovery of the T4:T1 ratio ≥ 0.9 (measured with a TOF-Watch SX)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in Time From Neuromuscular Reversal to Exit From OR</measure>
    <time_frame>Day 1</time_frame>
    <description>Difference in time from neuromuscular reversal to exit from OR was measured in minutes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in Time From Neuromuscular Reversal to Tracheal Extubation</measure>
    <time_frame>Day 1</time_frame>
    <description>Difference in time from neuromuscular reversal to tracheal extubation was measured in minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Length of Stay in PACU</measure>
    <time_frame>Day 1</time_frame>
    <description>Length of PACU stay measured in minutes.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Difference in Time to First Ambulation After Surgery</measure>
    <time_frame>From Day 1 up to 1 week, depending on individual recovery time</time_frame>
    <description>Time from end of anesthesia to the first subject ambulation in hours.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Spine Surgery</condition>
  <arm_group>
    <arm_group_label>Sugammadex group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg/kg of sugammadex, IV once at the end of the surgery. Dosing will be based on actual body weight not ideal body weight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neostigmine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 micrograms/kg (not to exceed 5 mg) and glycopyrrolate, 10 micrograms/kg (not to exceed 1 mg), IV once at the end of the surgery.
Dosing will be based on actual body weight not ideal body weight.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sugammadex</intervention_name>
    <description>once at the end of the surgery</description>
    <arm_group_label>Sugammadex group</arm_group_label>
    <other_name>Bridion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>once at the end of the surgery</description>
    <arm_group_label>Neostigmine group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Posterior spinal surgery

          2. Age ≥ 65 years

          3. American Society of Anesthesiologists (ASA) grade I-III

        Exclusion Criteria:

          1. Inability to obtain written informed consent

          2. Allergy to rocuronium or anesthetic agents used in the protocol

          3. Known or suspected neuromuscular disorders

          4. Significant renal disease with a serum creatinine ≥ 2 mg/dl

          5. Significant liver disease

          6. A family history of malignant hyperthermia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boris Mraovic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univesity of Missouri-Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University on Missouri Hospital</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 29, 2017</study_first_submitted>
  <study_first_submitted_qc>April 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2017</study_first_posted>
  <results_first_submitted>December 17, 2019</results_first_submitted>
  <results_first_submitted_qc>February 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 10, 2020</results_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Missouri-Columbia</investigator_affiliation>
    <investigator_full_name>Boris Mraovic</investigator_full_name>
    <investigator_title>Professor of Clinical Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>spine surgery</keyword>
  <keyword>neuromuscular blockade</keyword>
  <keyword>sugammadex</keyword>
  <keyword>elderly</keyword>
  <keyword>reversal</keyword>
  <keyword>neostigmine</keyword>
  <keyword>recovery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT03112993/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period
First subject on study: 30/MAY/2017; Last subject off study: 14/AUG/2018.
Locations: University Hospital and Missouri Orthopaedic Institute, University of Missouri, Columbia, Missouri, United States of America.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sugammadex Group</title>
          <description>2 mg/kg of sugammadex, IV once at the end of the surgery. Dosing will be based on actual body weight not ideal body weight.
sugammadex: once at the end of the surgery</description>
        </group>
        <group group_id="P2">
          <title>Neostigmine Group</title>
          <description>50 micrograms/kg (not to exceed 5 mg) and glycopyrrolate, 10 micrograms/kg (not to exceed 1 mg), IV once at the end of the surgery.
Dosing will be based on actual body weight not ideal body weight.
Neostigmine: once at the end of the surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sugammadex Group</title>
          <description>2 mg/kg of sugammadex, IV once at the end of the surgery. Dosing will be based on actual body weight not ideal body weight.
sugammadex: once at the end of the surgery</description>
        </group>
        <group group_id="B2">
          <title>Neostigmine Group</title>
          <description>50 micrograms/kg (not to exceed 5 mg) and glycopyrrolate, 10 micrograms/kg (not to exceed 1 mg), IV once at the end of the surgery.
Dosing will be based on actual body weight not ideal body weight.
Neostigmine: once at the end of the surgery</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.4" spread="4.7"/>
                    <measurement group_id="B2" value="71.2" spread="4.8"/>
                    <measurement group_id="B3" value="70.8" spread="4.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ASA Physical Status Classification</title>
          <description>American Society of Anesthesiologists (ASA) physical status (PS) classification system (scale range: ASA PS 1-6). Per study protocol, subject inclusion was dependent on classification as ASA PS 1-3 and these groups can be described as follows: ASA PS 1 (a normal healthy patient); ASA PS 2 (a patient with mild systemic disease); ASA PS 3 (a patient with severe systemic disease). ASA PS classification is determined by the anesthesiologist on the day of surgery following subject interview and physical assessment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>ASA PS 2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ASA PS 3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of surgery</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="175" spread="128"/>
                    <measurement group_id="B2" value="196" spread="96"/>
                    <measurement group_id="B3" value="185.5" spread="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>End of surgery to administration of reversal (min)</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.5" spread="2.0"/>
                    <measurement group_id="B2" value="4.8" spread="1.4"/>
                    <measurement group_id="B3" value="5.15" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Difference in Time of Neuromuscular Recovery From a Neuromuscular Moderate Blockade</title>
        <description>Speed of neuromuscular recovery in minutes measured by recovery of the T4:T1 ratio ≥ 0.9 (measured with a TOF-Watch SX)</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugammadex Group</title>
            <description>2 mg/kg of sugammadex, IV once at the end of the surgery.
Dosing will be based on actual body weight not ideal body weight.
sugammadex: once at the end of the surgery</description>
          </group>
          <group group_id="O2">
            <title>Neostigmine Group</title>
            <description>50 micrograms/kg (not to exceed 5 mg) and glycopyrrolate, 10 micrograms/kg (not to exceed 1 mg), IV once at the end of the surgery.
Dosing will be based on actual body weight not ideal body weight.
Neostigmine: once at the end of the surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Time of Neuromuscular Recovery From a Neuromuscular Moderate Blockade</title>
          <description>Speed of neuromuscular recovery in minutes measured by recovery of the T4:T1 ratio ≥ 0.9 (measured with a TOF-Watch SX)</description>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="2.2"/>
                    <measurement group_id="O2" value="26.29" spread="17.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Difference in Time From Neuromuscular Reversal to Exit From OR</title>
        <description>Difference in time from neuromuscular reversal to exit from OR was measured in minutes.</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugammadex Group</title>
            <description>2 mg/kg of sugammadex, IV once at the end of the surgery. Dosing will be based on actual body weight not ideal body weight.
sugammadex: once at the end of the surgery</description>
          </group>
          <group group_id="O2">
            <title>Neostigmine Group</title>
            <description>50 micrograms/kg (not to exceed 5 mg) and glycopyrrolate, 10 micrograms/kg (not to exceed 1 mg), IV once at the end of the surgery.
Dosing will be based on actual body weight not ideal body weight.
Neostigmine: once at the end of the surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Time From Neuromuscular Reversal to Exit From OR</title>
          <description>Difference in time from neuromuscular reversal to exit from OR was measured in minutes.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="2.2"/>
                    <measurement group_id="O2" value="19.8" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Time From Neuromuscular Reversal to Tracheal Extubation</title>
        <description>Difference in time from neuromuscular reversal to tracheal extubation was measured in minutes.</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugammadex Group</title>
            <description>2 mg/kg of sugammadex, IV once at the end of the surgery. Dosing will be based on actual body weight not ideal body weight.
sugammadex: once at the end of the surgery</description>
          </group>
          <group group_id="O2">
            <title>Neostigmine Group</title>
            <description>50 micrograms/kg (not to exceed 5 mg) and glycopyrrolate, 10 micrograms/kg (not to exceed 1 mg), IV once at the end of the surgery.
Dosing will be based on actual body weight not ideal body weight.
Neostigmine: once at the end of the surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Time From Neuromuscular Reversal to Tracheal Extubation</title>
          <description>Difference in time from neuromuscular reversal to tracheal extubation was measured in minutes.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="2.5"/>
                    <measurement group_id="O2" value="23.6" spread="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Length of Stay in PACU</title>
        <description>Length of PACU stay measured in minutes.</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugammadex Group</title>
            <description>2 mg/kg of sugammadex, IV once at the end of the surgery.
Dosing will be based on actual body weight not ideal body weight.
Sugammadex: once at the end of the surgery</description>
          </group>
          <group group_id="O2">
            <title>Neostigmine Group</title>
            <description>50 micrograms/kg (not to exceed 5 mg) and glycopyrrolate, 10 micrograms/kg (not to exceed 1 mg), IV once at the end of the surgery.
Dosing will be based on actual body weight not ideal body weight.
Neostigmine: once at the end of the surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Length of Stay in PACU</title>
          <description>Length of PACU stay measured in minutes.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.4" spread="16.5"/>
                    <measurement group_id="O2" value="85.3" spread="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Difference in Time to First Ambulation After Surgery</title>
        <description>Time from end of anesthesia to the first subject ambulation in hours.</description>
        <time_frame>From Day 1 up to 1 week, depending on individual recovery time</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugammadex Group</title>
            <description>2 mg/kg of sugammadex, IV once at the end of the surgery.
Dosing will be based on actual body weight not ideal body weight.
Sugammadex: once at the end of the surgery</description>
          </group>
          <group group_id="O2">
            <title>Neostigmine Group</title>
            <description>50 micrograms/kg (not to exceed 5 mg) and glycopyrrolate, 10 micrograms/kg (not to exceed 1 mg), IV once at the end of the surgery.
Dosing will be based on actual body weight not ideal body weight.
Neostigmine: once at the end of the surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Time to First Ambulation After Surgery</title>
          <description>Time from end of anesthesia to the first subject ambulation in hours.</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" spread="14.6"/>
                    <measurement group_id="O2" value="17.8" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Each subjects was assessed for all-cause mortality, serious adverse events, and other adverse events across their entire duration of study participation, which was the time a subject provided written informed consent until their inpatient hospital discharge following surgery. This time frame was on average 4 days.</time_frame>
      <desc>All-cause mortality, serious adverse events, and other adverse events were systematically assessed by study physician investigators through regular investigator assessment, and through review of subjects' electronic medical records during study participation.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sugammadex Group</title>
          <description>2 mg/kg of sugammadex, IV once at the end of the surgery.
Dosing will be based on actual body weight not ideal body weight.
Sugammadex: once at the end of the surgery</description>
        </group>
        <group group_id="E2">
          <title>Neostigmine Group</title>
          <description>50 micrograms/kg (not to exceed 5 mg) and glycopyrrolate, 10 micrograms/kg (not to exceed 1 mg), IV once at the end of the surgery.
Dosing will be based on actual body weight not ideal body weight.
Neostigmine: once at the end of the surgery</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>ICU admission</sub_title>
                <description>Unanticipated ICU admission due to surgical bleeding</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Blood transfusion</sub_title>
                <description>Perioperative blood transfusion</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Prolonged hospitalization</sub_title>
                <description>Longer hospital stay than anticipated</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Boris Mraovic, MD, Professor of Clinical Anesthesiology</name_or_title>
      <organization>University of Missouri</organization>
      <phone>573-882-2568</phone>
      <email>mraovicb@health.missouri.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

